FDA Office of Regulatory Affairs
This article was originally published in The Tan Sheet
Executive Summary
Recalls enterprise system under development will be "agency-wide, unified database that will provide accurate, real-time information, as well as archival data" accessible to industry, consumers, other regulatory bodies or FDA personnel, Associate Commissioner for Regulatory Affairs Dennis Baker announces at FDLI 44th Annual Educational Conference. Saying FDA is "reengineering the recall process," Baker explains system is based on prototype used by Center for Devices & Radiological Health for last three years. Agency is considering manufacturer incentive plan to encourage compliance by reducing inspection frequency after two consecutive positive reviews. FDAer notes 12.4% of 15,146 FY 2000 plant inspections were violative. Of those, 19.1% were human drugs, 10.2% foods and 13.9% cosmetics
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning